Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | MEN1 | O00255 | 6/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | HPGD | P15428 | 4/20 | 0.69 |
| ▸ | NPC1 | O15118 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2644228 | 0.88 | ALDH1A1 (0.72) | ALDH1A1MEN1KMT2ARAB9AHPGD | |
| SCHEMBL2644794 | 0.86 | MAPK10 (0.72) | ALDH1A1MEN1KMT2ARAB9AHPGD | |
| SCHEMBL2644452 | 0.85 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2ARAB9AHPGD | |
| SCHEMBL4693720 | 0.85 | ALDH1A1 (0.73) | ALDH1A1MEN1KMT2ARAB9AHPGD | |
| SCHEMBL2657690 | 0.83 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2ARAB9AHPGD | |
| SCHEMBL2643661 | 0.83 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2ARAB9AHPGD | |
| SCHEMBL15281388 | 0.82 | RAB9A (1.00) | ALDH1A1MEN1KMT2ARAB9AHPGD | |
| SCHEMBL3285611 | 0.80 | MAPK10 (1.00) | ALDH1A1MEN1KMT2ARAB9AHPGD | |
| SCHEMBL14580981 | 0.79 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2ARAB9AHPGD | |
| SCHEMBL2644838 | 0.78 | MEN1 (0.55) | ALDH1A1MEN1KMT2ARAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620425-B1 | SUBSTITUTED 3-CYANOTHIOPHENE ACETAMIDES AS GLUCAGON RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-12-24 | — | — | EP | claimed |
| US-7138529-B2 | Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-11-21 | — | — | US | claimed |
| EP-1620425-A1 | SUBSTITUTED 3-CYANOTHIOPHENE ACETAMIDES AS GLUCAGON RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-01 | — | — | EP | claimed |
| WO-2004092156-A1 | SUBSTITUTED 3-CYANOTHIOPHENE ACETAMIDES AS GLUCAGON RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-28 | — | — | WO | claimed |
| US-20040209943-A1 | Novel substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | ERICKSON SHAWN DAVID (US) | 2004-10-21 | — | — | US | claimed |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | REMD Biotherapeutics, Inc | 2017-05-25 | — | — | US | disclosed |
| EP-1620425-B1 | SUBSTITUTED 3-CYANOTHIOPHENE ACETAMIDES AS GLUCAGON RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-12-24 | — | — | EP | disclosed |
| US-7138529-B2 | Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7138529-B2 | Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7138529-B2 | Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1620425-A1 | SUBSTITUTED 3-CYANOTHIOPHENE ACETAMIDES AS GLUCAGON RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004092156-A1 | SUBSTITUTED 3-CYANOTHIOPHENE ACETAMIDES AS GLUCAGON RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209943-A1 | Novel substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | ERICKSON SHAWN DAVID (US) | 2004-10-21 | — | — | US | disclosed |
| US-20040209943-A1 | Novel substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | ERICKSON SHAWN DAVID (US) | 2004-10-21 | — | — | US | disclosed |
| US-20040209943-A1 | Novel substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | ERICKSON SHAWN DAVID (US) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209943-A1 | Novel substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | GLP1R, GCGR, GPR119 | ALDH1A1 1214/4885MEN1 1036/4885KMT2A 3567/4885 |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | GLP1R, GCGR, GIPR | ALDH1A1 3069/4885MEN1 4200/4885KMT2A 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.